Why So Many Clinicians Are Confused About Peptide Regulations Right Now

By Lauren Supra, RN, BC-FMP
Founder of Advera Care | Creator of Peptide Therapy in Clinical Practice

If you are a healthcare professional trying to understand peptide therapy right now, you are probably realizing very quickly how confusing the regulatory side of this field has become.

One minute a peptide is being discussed all over clinical and wellness spaces. The next minute people are hearing about restrictions, FDA review, compounding concerns, shortage lists, or pharmacies pulling products altogether.

And honestly, most clinicians were never taught how to interpret any of this. That is where a lot of the frustration comes from.

Providers are trying to understand:

- what is FDA approved
- what is compounded
- what is investigational
- what “research use only” actually means
- what 503A and 503B pharmacies are
- what peptides are currently under FDA review
- and what all of this means for real patient care

Most clinicians are not looking for shortcuts here. They are trying to understand the field responsibly before discussing it with patients. But the education surrounding peptide therapy has become extremely scattered.

A lot of what healthcare professionals are seeing online is either:

- oversimplified
- fear driven
- completely inaccurate
- or heavily biased in one direction

That leaves clinicians stuck trying to sort through regulatory information, clinical discussions, social media claims, and patient questions all at the same time. And patients are absolutely asking about this.

Why Certain Peptides Came Under More FDA Attention

One of the biggest misunderstandings in peptide therapy is the assumption that all peptides fall under the same category. They do not.

Some peptides are FDA-approved medications. Some are compounded under specific circumstances. Some are still being researched. Others have been sold online as “research use only” substances despite being openly discussed throughout wellness spaces.

As peptide interest rapidly increased, regulatory agencies also started paying closer attention to:

- compounding practices
- product quality
- marketing claims
- sourcing
- patient safety concerns
- and whether certain bulk substances met legal criteria for compounding

That is a large part of why certain peptides started coming under heavier review. The issue is that many clinicians were never educated on the regulatory side of compounded medications during traditional medical training, let alone peptide therapy specifically.

So now healthcare professionals are trying to learn an entirely separate area of medicine while also trying to determine what information is reliable and what is not.

The Current FDA Review Discussion Around Certain Peptides

One reason clinicians are paying even closer attention right now is because several peptides have been discussed as part of ongoing FDA compounding and bulk substance review conversations.

Many healthcare professionals started hearing discussions surrounding peptides such as:

• BPC-157

• CJC-1295

• Ipamorelin

• Thymosin alpha-1

• MOTS-C

• AOD-9604

• GHK-Cu

• and others being evaluated within broader regulatory and compounding discussions.

That immediately created confusion throughout clinical spaces because many providers were trying to determine:

• whether these peptides could still be compounded

• whether pharmacies would continue offering them

• what the FDA was actually reviewing

• and what all of this meant for patient care moving forward

The difficult part is that most clinicians were never formally taught how FDA bulk substance nominations, compounding regulations, or Section 503A review processes actually work.

So providers are left trying to interpret rapidly changing information while also attempting to responsibly educate patients at the same time.

And unfortunately, social media often oversimplifies these discussions into extreme headlines instead of helping healthcare professionals understand the actual regulatory process behind them.

The issue is that many clinicians were never educated on the regulatory side of compounded medications during traditional medical training, let alone peptide therapy specifically.

So now healthcare professionals are trying to learn an entirely separate area of medicine while also trying to determine what information is reliable and what is not.

Why Clinicians Feel So Hesitant Right Now

A lot of providers feel uncomfortable discussing peptide therapy because they do not want to say the wrong thing, recommend something inappropriate, or step outside responsible practice. That hesitation is understandable.

Healthcare professionals carry real responsibility when patients trust them with their care. And unfortunately, peptide therapy has become filled with strong opinions from every direction.

Some people act like peptides are the answer to everything. Others immediately dismiss the entire field altogether. Neither approach helps clinicians think critically. Healthcare professionals need actual education. They don’t need to rely on protocols thrown around online, influencer opinions, or marketing disguised as education.

Clinicians need to understand:
- physiology
- mechanisms of action
- evidence limitations
- patient selection considerations
- safety concerns
- documentation
- informed consent
- compounding standards
- and how to properly educate patients

Because understanding peptide therapy is much bigger than memorizing what a peptide is “used for.”

The Bigger Problem Is The Educational Gap

The confusion surrounding peptide regulations is exposing a much larger issue inside healthcare:

Most clinicians were never formally taught peptide therapy in a structured way. Not in school, in traditional training, or in a way that connected the physiology, the clinical reasoning, the regulations, and the patient education side together.

So what happens? Healthcare professionals either avoid the field completely, or try piecing information together themselves online. That is where things become dangerous. Because patients are already hearing about peptide therapy whether clinicians are comfortable discussing it or not. Patients are researching peptides online, asking about GLP-1 medications, and hearing about BPC-157, thymosin alpha-1, CJC-1295, ipamorelin, MOTS-C, and many others.

Patients are trying to understand recovery, inflammation, metabolism, body composition, longevity, sexual health, energy, and overall function. And many of them are walking into appointments hoping their provider can help them understand what they are hearing.

Healthcare professionals deserve education that actually prepares them for those conversations.

Why Education Matters More Than Ever

Regardless of what future FDA decisions look like, clinicians still need to understand this field well enough to think critically through it.

That means understanding:
- what peptides actually are
- how they function in the body
- where evidence exists
- where limitations still exist
- what is FDA approved
- what is investigational
- what responsible patient education looks like
- and how to navigate peptide therapy without falling into misinformation from either side

Because this field is growing quickly. Research continues expanding. Patients continue asking questions. Clinics continue exploring peptide therapy. And healthcare professionals are being forced to catch up to an area of medicine that most were never formally taught. That is exactly why I created Peptide Therapy in Clinical Practice.

The goal was to create structured education that helps healthcare professionals actually understand peptide therapy from a physiological and clinical perspective before ever trying to implement it into practice. Because patients deserve providers who understand what they are talking about. And clinicians deserve education that helps them approach this field with clarity instead of confusion.

Conclusion

Right now, peptide therapy sits in a very complicated place inside healthcare. As Research expands, patient interests grow, regulations continue to evolve, and clinicians try to figure out where all of this fits into responsible patient care.

That is not easy when most providers were never formally educated in this field to begin with. But avoiding peptide therapy altogether will not stop patients from asking about it.

Healthcare professionals need better education so they can evaluate this field responsibly, educate patients honestly, and think critically through what may or may not make sense in clinical practice. Because at the end of the day, this should never be about blindly following claims or rejecting the field entirely. It should be about helping clinicians become educated enough to make thoughtful, informed decisions for the patients trusting them with their care.

References

U.S. Food and Drug Administration. (2024). Compounding and the FDA: Questions and answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

U.S. Food and Drug Administration. (2024). Human drug compounding. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding

U.S. Food and Drug Administration. (2025). Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and

Alliance for Pharmacy Compounding. (2024). 503A and 503B compounding explained. https://a4pc.org

Hampp, C., Kang, E. M., & Borders-Hemphill, V. (2022). Use of compounded medications in the United States. Journal of the American Pharmacists Association, 62(5), 1527–1534. https://doi.org/10.1016/j.japh.2022.05.009